Biocon has signed License and Supply Agreement with a subsidiary of China Medical System Holdings (CMS) for three Generic Formulation products in Greater China. This development is in line with the company’s long-term generic formulations strategy and expands its Generic Formulations business footprint to the Chinese pharmaceuticals market, which is the second largest pharmaceutical market in the world.
Under the terms of the agreement, the company will be responsible for the development, manufacturing and supply of the products. CMS will be responsible for registration and commercialization of the products in China. The initial term of the agreement shall be for 10 years from the date of commercialization, extendable by two years on a product basis by mutual consent. This collaboration can be extended to a broader portfolio in future.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
